Clinical Trials
156 trialsClinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
Yuhan Corporation
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NRG Oncology
FORTITUDE-301
Amgen
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
BerGenBio ASA
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
CAR T Cells in Mesothelin Expressing Cancers
University of Pennsylvania
To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Celltrion
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
The First Affiliated Hospital of Xiamen University
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
CORIN
Sun Yat-sen University
AUTOMAN
Shanghai Chest Hospital
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
National Institutes of Health Clinical Center (CC)
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma
Guangzhou Institute of Respiratory Disease
NintNivo
AIO-Studien-gGmbH
BLISS
Hospital Israelita Albert Einstein
Radiation in Stage I or Stage II Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Canadian Cancer Trials Group
Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002)
Fudan University
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
Cantargia AB
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Eastern Cooperative Oncology Group
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
Eastern Cooperative Oncology Group
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
Eastern Cooperative Oncology Group
Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma
Sun Yat-sen University
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
Memorial Sloan Kettering Cancer Center
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
US NAB With ROSE Versus US FNAB With no ROSE
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)
Swiss Cancer Institute
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
University of Colorado, Denver
Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy
Abramson Cancer Center at Penn Medicine
Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
Wake Forest University Health Sciences
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Novartis
LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Novartis
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Novartis
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute